RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorFujian Medical University

About this trial

Why is this study being done? RET gene alterations occur in only 5-10 % of papillary thyroid cancers, but they can change how surgeons treat the disease. Gene testing is costly and not always performed, so many RET-positive tumours are missed. Researchers have built a computer program (artificial-intelligence or "AI" model) that reads routine thyroid ultrasound images and predicts whether the tumour carries a RET alteration and whether the cancer has already spread to lymph-nodes in the side of the neck.

What will happen in this study?

About 800 adults who are scheduled for thyroid-cancer surgery will take part. Each participant will:

* have a standard pre-operative ultrasound exam (no extra scanning time), * give a routine fine-needle sample for a 14-gene panel test (results in 24 h), and * allow the AI model to analyse the ultrasound images in the background. Doctors making treatment decisions will not see the AI result. After surgery, the research team will compare the AI predictions with the gene-panel result and the final pathology report.

Main goal: To find out how accurately the AI model detects RET alterations. Secondary goals: To measure the model's ability to predict lymph-node spread, and to compare costs between ultrasound-only prediction and full gene testing.

Benefits and risks: Participants will receive the current standard of care; there is no added risk beyond the usual ultrasound and needle biopsy. The study could lead to faster, less expensive ways to identify high-risk thyroid cancers in the future.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-75 years, able to provide written informed consent.

Pre-operative ultrasound findings highly suggestive of papillary thyroid carcinoma.

Planned thyroidectomy (any extent) at a participating institution.

Willing to undergo rapid 11-gene next-generation sequencing (NGS) panel and allow use of ultrasound DICOM images for AI analysis.

Disqualifiers

Prior thyroid or major neck surgery.

Known medullary thyroid carcinoma, anaplastic carcinoma, or metastatic disease outside the neck.

Multiple endocrine neoplasia (MEN) syndromes or clinical suspicion of multi-gland disease.

Pregnant or breastfeeding.

Trial population

Consecutive adults with ultrasound-suspected papillary thyroid carcinoma scheduled for thyroidectomy at participating centers.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • AI-Ultrasound RET Prediction

    Diagnostic test

    Deep-learning algorithm that analyses thyroid ultrasound DICOM images and outputs a probability score for RET gene alteration and lateral-neck lymph-node metastasis; run offline, results blinded to treating surgeons.

Treatment groups

800 Participants
are divided into 1 treatment group
Group A: Prospective Thyroid Cancer Cohort1 intervention

Trial outcomes

Primary outcomes

1

Area Under the ROC Curve (AUC) for AI-Ultrasound Detection of RET Alterations

The receiver-operating-characteristic area under the curve comparing the AI-generated probability score against the reference 14-gene next-generation sequencing (NGS) result for RET fusion or point mutation. AUC calculated with 95 % confidence interval via DeLong method.

Time frame
Date of surgery (assessment completed when gene-panel result is available)

Secondary outcomes

1

Sensitivity and Specificity of AI-Ultrasound for Detecting RET Alterations

Using the threshold that maximized the Youden index in the development set, calculate sensitivity (true-positive rate) and specificity (true-negative rate) of the AI model versus 11-gene NGS reference for RET fusion or point mutation. Results reported with 95 % confidence intervals.

Time frame
Date of surgery (assessment completed when NGS result is available)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fujian Medical University

Lead sponsor

Fujian Medical University Union Hospital

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: